TREATMENT OF MYOCARDIAL INFARCTION WITH REGENERATED HIGH-DENSITY LIPOPROTEIN Russian patent published in 2023 - IPC A61K31/56 A61K31/198 A61K31/70 A61P3/06 A61P9/10 

FIELD: medicine.

SUBSTANCE: group of inventions relates to methods of increasing reverse cholesterol transport (RCT) in a patient after acute myocardial infarction (MI). A method of increasing reverse cholesterol transport (RCT) in a human after an acute myocardial infarction (MI) includes intravenously administering to a patient, within seven (7) days after the acute MI, a reduced high-density lipoprotein (rHDL) formulation containing an apolipoprotein or a fragment thereof, a lipid, stabilizer, where the stabilizer is sucrose, and, optionally, detergent, taken in a certain amount and ratio; wherein the patient is administered an angiographic contrast agent after an acute myocardial infarction and prior to the initial administration of the rHDL formulation; and subsequent intravenous administration of the rHDL formulation to the human weekly for at least four (4) weeks; which leads to an increase in reverse cholesterol transport (RCT) in humans without causing significant changes in liver and/or kidney function. A method for increasing reverse cholesterol transport (RCT) in a human patient following an acute myocardial infarction (MI) comprises intravenously administering to the patient, within seven (7) days following the acute MI of a reduced high-density lipoprotein (rHDL) formulation containing apoA-I, phosphatidylcholine, stabilizer, where the stabilizer is sucrose, and sodium cholate, taken in a certain amount and ratio; wherein the patient is administered an angiographic contrast agent after an acute myocardial infarction and prior to the initial administration of the rHDL formulation; subsequent intravenous administration of the rHDL formulation to a human weekly for at least four (4) weeks; resulting in an increase in reverse cholesterol transport (RCT) in a human patient without causing significant changes in liver and/or kidney function, while a significant change in liver function is defined based on an ALT value greater than 2 or 3 times the upper limit of normal (ULN); or an increase in the level of total bilirubin to an indicator at least 1.5–2 times higher than the ULN; and a significant change in kidney function is defined as a serum creatinine greater than or 1.2–1.5 times baseline and/or an eGFR significantly less than 90 ml/min/m², including less than 90 ml/min/1.73 m².

EFFECT: above method allows to improve the RCT in the period when reverse cholesterol transport is significantly impaired after acute MI or it is used as an improved way to increase RCT in the treatment of acute MI.

37 cl, 15 dwg, 24 tbl, 3 ex